APOIMMUNE, INC

Company Information

Company Name
APOIMMUNE, INC
Address
APOIMMUNE, INC
1044 E CHESTNUT ST
LOUISVILLE, KY, 40204
Phone
n/a
URL
n/a
DUNS
140646345
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$2,393,963.00
5
SBIR Phase II
$1,636,799.00
1
STTR Phase I
$428,300.00
2
Chart code to be here

Award List

  1. A NOVEL APPROACH TO PREVENT GRAFT-VERSUS HOST DISEASE

    Amount: $100,000.00

    DESCRIPTION (provided by the applicant): Bone marrow transfusion (BMT) holds the potential to cure many blood diseases. However, BMT recipients often develop graft-versus-host disease (GvHD), a life-t ...

    SBIR Phase I 2002 Department of Health and Human Services
  2. A NOVEL ADJUVANT FOR TUMQR VACCINATION

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Cancer continues to be a leading cause of death in the U.S. and in many other countries. Cancers develop and spread within the body when tumor cells are not detec ...

    STTR Phase I 2004 Department of Health and Human Services
  3. Chimeric CD80-SA as a Novel Cancer Vaccine

    Amount: $750,804.00

    DESCRIPTION (provided by applicant): Cancer is one of the major causes of death in the U.S. and many developed countries with an estimated economic burden of over 100 billion dollars in direct and ind ...

    SBIR Phase I 2005 Department of Health and Human Services
  4. ApoFasL: a Novel Immunotherapeutic for T1D

    Amount: $421,676.00

    DESCRIPTION (provided by applicant): Type 1 Diabetes (T1D) is an autoimmune disease that targets insulin secreting pancreatic beta cells for destruction and remains a major cause of morbidity and mort ...

    SBIR Phase I 2007 Department of Health and Human Services
  5. ApoVax-SVN as a Novel Vaccine for Cancer Immunotherapy

    Amount: $328,300.00

    DESCRIPTION (provided by applicant): The main objective of this proposal is to develop a novel cancer vaccine, ApoVax-SVN(tm) based on the use of a proprietary costimulatory chimeric ligand, 4-1BBL, d ...

    STTR Phase I 2007 Department of Health and Human Services
  6. ApoVax104-HPV as a Novel Vaccine for Cervical Cancer

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Various cancer vaccines based on tumor associated antigens (TAAs) or tumor specific antigens (TSAs) have shown efficacy in preclinical models. However, their ther ...

    SBIR Phase I 2007 Department of Health and Human Services
  7. ApoVax104-HPV as a Novel Vaccine for Cervical Cancer

    Amount: $1,636,799.00

    DESCRIPTION (provided by applicant): Cervical cancer is one of the most common cancers affecting women and is a worldwide health problem. Unlike most cancers, cervical cancer is caused by a virus - t ...

    SBIR Phase II 2008 Department of Health and Human Services
  8. ApoVax104-TB as a Novel Vaccine for Tuberculosis

    Amount: $821,483.00

    DESCRIPTION (provided by applicant): The objective of this NIAID Advanced STTR Phase I proposal is to combine the strengths of academic investigators from the fields of immunology and animal disease m ...

    SBIR Phase I 2008 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government